Weekly Bulletin

IDCRC Profile: Natalia Jimenez-Truque, MSCI, PhD

Read an interview with Natalia Jimenez-Truque, MSCI, PhD, Research Assistant Professor, Pediatric Infectious Diseases, Vaccine and Treatment Evaluation Unit (VTEU), Vanderbilt University.

“The IDCRC is able to get an amazing group of experts in infectious diseases and vaccines to work together to tackle some of the most pressing issues in the field. The myriad of studies that have been launched and conducted in response to the pandemic highlight the good things that can come when great minds come together with a common goal.”

READ MORE
 

Publications

NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: 

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

 

View recent publications below:

  • Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
     
  • Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
     
  • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
     
  • Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
     
  • SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
     
  • Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
 

In The News

Dr. Barney Graham, deputy director of the NIH Vaccine Research Center (VRC) and chief of the Viral Pathogenesis Laboratory, is retiring after more than 20 years as an investigator at VRC

Dr. Graham’s career spans numerous pathogens and disciplines. He is an immunologist, virologist, vaccinologist, and clinical trials physician whose work has focused on respiratory viral pathogens, pandemic preparedness, and emerging viral diseases. Dr. Graham led the VRC development efforts for RSV, influenza, and COVID-19 vaccines, among many other noteworthy achievements. In addition, he has been a consummate mentor and teacher to many researchers.

He obtained his MD from the University of Kansas School of Medicine in 1979 and completed a clinical fellowship in infectious diseases. He earned a PhD in microbiology and immunology at Vanderbilt University School of Medicine in 1991, where he became a professor of medicine.

In 2000, Dr. Graham was recruited as one of the founding investigators for the VRC and he has been involved in vaccine design and clinical evaluation of candidate vaccines for more than 30 years. He has been an exemplary investigator and leader not only at the VRC, but in the global biomedical community, where he has donated much of his time and expertise as an advisor to the WHO and many other organizations. His insightful, inventive, and patient approach to research will be greatly missed among the VRC, NIAID, and NIH community.

READ MORE
 

Training

Mentee Profile: Zheyi Teoh, MD, Pediatric Infectious Diseases Fellow, Cincinnati Children’s

As an ID fellow, Dr. Teoh has broad interests that he hopes to develop, but he is specifically interested in epidemiology and public health research.

VIEW PROFILE
IDCRC TRAINING
 

Mentoring Lecture Archive

Maximizing the Mentor-Mentee Relationship
Presenter: Dr. Monica Gandhi, University of California San Francisco

VIDEO ARCHIVE
 

Call for Applications: Advanced Course of Vaccinology (ADVAC 2022) – Due November 15

ADVAC is a two-week training program for decision-makers, including academia, industry, governmental and non-governmental agencies. The course aims to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the various aspects of vaccinology (immunology, vaccine development, clinical trials, regulatory processes, vaccine-specific issues including new vaccines, vaccination strategies and policies, program implementation, humanitarian emergencies, social, economic, political and ethical issues, financing, and communications).

READ MORE
 

Funding

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) – Due January 7, 2022

This FOA seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS.

READ MORE
 

Job Postings

View details on current job openings:

  • Indiana University Department of Microbiology and Immunology is looking for a virologist and a bacteriologist to join the faculty
    ​
  • Fred Hutch's Vaccine and Infectious Disease Division is accepting applications for a faculty position in the Biostatistics, Bioinformatics and Epidemiology Program
     
  • Browse nearly 200 ID/HIV Medicine job postings at the IDSA Career Center
 

Events

HIV Vaccine Trials Network (HVTN)/COVID-19 Prevention Network (CoVPN) Virtual Conference, October 18-20

Event Password: HVTNCOVPN2021

For any questions about the meeting, please email vtn.travel@hvtn.org.

REGISTER
ACCESS EVENT
 

Save the Date: 3rd IDCRC Annual Meeting

Monday, January 24, 2022 from 9:00 a.m.-5:00 p.m. ET
Tuesday, January 25, 2022 from 9:00 a.m.-noon ET

 

IDCRC Studies

Active Studies
Recruiting Volunteers

  • Gritstone Second Generation COVID-19 Vaccine, CORAL Program
     

  • Moderna’s mRNA-1273 vaccine, the KidCOVE Study
     
  • SARS-CoV-2 Vaccines in Pregnancy and Postpartum, the MOMI-VAX Study
     
  • Heterologous Prime Boost, Mix and Match Study
     
  • Mucosal immunity against GC after 4CMenB Vaccination

Fully Enrolled Studies
in Follow-up

  • Moderna’s mRNA-1273 vaccine, The COVE Study™
     

  • Moderna’s mRNA-1273.351 Variant vaccine
     

  • AstraZeneca Study of AZD1222
     

  • The ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine
     

  • Novavax Study of NVX-CoV2373
     

  • Regeneron’s 10933 and 10987 Monoclonal Antibodies, the REGN-COV2 Study
     

  • Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study
     
  • SARS-CoV-2/COVID-19 PREVALENCE STUDY, The COMPASS Study
IDCRC ACTIVE AND COMPLETED STUDIES
 

IDCRC Concept Quick Stats

ICP Status

  • Approved: 26

  • Administratively Not Supported: 16

  • Revise and Resubmit: 7

  • Withdrawn: 7

  • Liaisons: 2

  • EWGs: 2

  • Not Approved: 28

  • EMT: 1

  • Other: 5

EWG Assignment

  • COVID: 70

  • Respiratory: 9

  • Sexually Transmitted Infections: 5

  • Malaria and Tropical Dis.: 3

  • Enteric Inf.: 2

  • Emerging Infections: 5

ECP Status

  • Protocol Development: 7

  • IDCRC Study Underway: 2

  • Submitted to ACTIV Mab Program per DMID: 1

  • Transitioned to CoVPN trial: 1

  • Transitioned to ACTT 2: 1

  • Funded by NIAID via other mechanism: 1

  • Pending: 8

  • Not approved: 0

  • In process: 4

  • On hold: 4

NOTE: Protocols Transitioned to IDCRC for Protocol Implementation: 5

IDCRC STUDIES
 

Communication Resources

COMMUNICATION TOOLKIT
 

Please submit IDCRC news to epthomp@emory.edu for inclusion in the monthly newsletter and IDCRC.org.

VISIT IDCRC WEBSITE
SUBSCRIBE TO NEWSLETTER
Twitter
 
Woodruff Health Sciences Center
Emory University
1440 Clifton Road NE
Atlanta, GA 30322, United States

Subscribe

Preferences  |  Unsubscribe